AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12733709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Number of subjects: 59
Study 12733709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 59
Study 10227010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Number of subjects: 72
Study 10227010 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 hormone replacement therapy
Number of subjects: 72
Study 10227010 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-progestin therapy
Number of subjects: 72
Study 8755201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/ml mitomycin C
Number of subjects: 26
Study 8755201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml mitomycin C
Number of subjects: 26
Study 8755201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/ml mitomycin C
Number of subjects: 26
Study 8755201 — intervention group
Group type: COMPARATOR
Intervention: Control (no MMC)
Number of subjects: 26
Study 1848996 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (control) - standard alternating chemotherapy regimen
Number of subjects: 234
Study 1848996 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (investigative) - simultaneous administration of cyclophosphamide + lomustine alternating with cyclophosphamide + doxorubicin, and doxorubicin + lomustine
Number of subjects: 234
Study 1848996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 234
Study 1848996 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 234
Study 1848996 — intervention group
Group type: COMPARATOR
Intervention: Regimen A
Number of subjects: 234
Study 7075640 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg tid)
Number of subjects: 17
Study 7075640 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.1 mg tid)
Number of subjects: 17
Study 31954996 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary task
Number of subjects: 191
Study 31954996 — intervention group
Group type: EXPERIMENTAL
Intervention: Social task
Number of subjects: 191
Study 30539384 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg/day for 6 months
Number of subjects: 60
Study 30539384 — intervention group
Group type: COMPARATOR
Intervention: Oral rivaroxaban for 6 months (Control)
Number of subjects: 60
Study 28371242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT) for 5 days
Number of subjects: 24
Study 28371242 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo spray for 5 days
Number of subjects: 24
Study 26015309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic 15 mg MPA
Number of subjects: 80
Study 26015309 — intervention group
Group type: COMPARATOR
Intervention: Continuous 15 mg MPA
Number of subjects: 80
Study 23880454 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion arteriography (CA)
Number of subjects: 559
Study 23880454 — intervention group
Group type: COMPARATOR
Intervention: No completion arteriography (no CA)
Number of subjects: 559
Study 21206508 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched low-glycemic index (LG) diet
Number of subjects: 64
Study 21206508 — intervention group
Group type: COMPARATOR
Intervention: Healthy American (HA) diet
Number of subjects: 64
Study 19657698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential decrease group (group 1: 0.9 < R(2) ≤ 1.0)
Number of subjects: 122
Study 19657698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nearly exponential decrease group (group 2: 0.5 < R(2) ≤ 0.9)
Number of subjects: 122
Study 19657698 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clearance group (group 3: 0.5 ≤ R(2))
Number of subjects: 122
Study 19657698 — intervention group
Group type: COMPARATOR
Intervention: Exponential decrease group (group 1) vs. Nearly exponential decrease group (group 2) and Randomized clearance group (group 3) in stage II rectal cancer
Number of subjects: 122
Study 17412858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary control reducing calorie intake by 200 to 300 kcal per day and a six-month regimen of regular physical activity (600 to 750 kcal per week).
Number of subjects: 53
Study 17412858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 53
Study 15837446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Translating ATP III guidelines into clinical practice
Number of subjects: 0
Study 12203856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 0
Study 9657561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 336 microg x day(‐1)
Number of subjects: 24
Study 9657561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8593713 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily) for 6 weeks
Number of subjects: 20
Study 8593713 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily) for 12 weeks
Number of subjects: 20
Study 2675580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg twice daily
Number of subjects: 24
Study 2675580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1090796 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitrogen mustard
Number of subjects: 0
Study 1090796 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam therapy
Number of subjects: 0
Study 1090796 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent chemotherapy
Number of subjects: 0
Study 1090796 — intervention group
Group type: COMPARATOR
Intervention: Topical therapy and external irradiation
Number of subjects: 0
Study 31928862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfapump (AP) system
Number of subjects: 0
Study 31928862 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 30602354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 100
Study 30602354 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 100
Study 30602354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (after excluding stroke mimics and patients with modified Rankin Scale score of >1 before stroke)
Number of subjects: 100
Study 30602354 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (after excluding stroke mimics and patients with modified Rankin Scale score of >1 before stroke)
Number of subjects: 100
Study 28758716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% TiF4 gel applied three times (TiF4 3)
Number of subjects: 60
Study 28758716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% TiF4 gel applied twice (TiF4 2)
Number of subjects: 60
Study 28758716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% TiF4 gel applied once (TiF4 1)
Number of subjects: 60
Study 28758716 — intervention group
Group type: COMPARATOR
Intervention: Control group (C1) - no treatment, 2 days of erosive/abrasive cycling
Number of subjects: 60
Study 28758716 — intervention group
Group type: COMPARATOR
Intervention: Control group (C2) - no treatment, 4 days of erosive/abrasive cycling
Number of subjects: 60
Study 28758716 — intervention group
Group type: COMPARATOR
Intervention: Control group (C3) - no treatment, 6 days of erosive/abrasive cycling
Number of subjects: 60
Study 28758716 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro uneroded samples (UN)
Number of subjects: 60
Study 26542508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor or prasugrel
Number of subjects: 1000
Study 26542508 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1000
Study 23473987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (anticraving substance) administered for 3 months
Number of subjects: 34
Study 21438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP) group therapy over a 2-month period
Number of subjects: 100
Study 21438799 — intervention group
Group type: COMPARATOR
Intervention: Labor Rehabilitation (LR) standard-of-care treatment
Number of subjects: 100
Study 21438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP) group therapy
Number of subjects: 100
Study 19231261 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious high current density stimulation (condition 2)
Number of subjects: 12
Study 19231261 — intervention group
Group type: COMPARATOR
Intervention: Noxious low current density stimulation (condition 1)
Number of subjects: 12
Study 16453054 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week, twice-weekly exercise program (EX1)
Number of subjects: 91
Study 16453054 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week, twice-weekly exercise program (EX2)
Number of subjects: 91
Study 16453054 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention in hypertensive subjects
Number of subjects: 91
Study 16453054 — intervention group
Group type: COMPARATOR
Intervention: Control group (relaxation classes)
Number of subjects: 91
Study 15112279 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized, nutrition‐focused patient care (oral nutritional support and home total parenteral nutrition [TPN]) along with COX inhibitor (indomethacin, 50 mg twice daily) and EPO (15‐40,000 units per week)
Number of subjects: 309
Study 11665788 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors (PDEI)
Number of subjects: 29
Study 11665788 — intervention group
Group type: COMPARATOR
Intervention: Catecholamines (CA)
Number of subjects: 29
Study 9743450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic matrix tablet (ER)
Number of subjects: 58
Study 9743450 — intervention group
Group type: COMPARATOR
Intervention: Push‐pull osmotic pump tablet (XL)
Number of subjects: 58
Study 9743450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic matrix tablet (ER) with food
Number of subjects: 58
Study 9743450 — intervention group
Group type: COMPARATOR
Intervention: Push‐pull osmotic pump tablet (XL) with food
Number of subjects: 58
Study 7974365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of heparin (LDH)
Number of subjects: 500
Study 7974365 — intervention group
Group type: COMPARATOR
Intervention: Heparin-dihydergot (HDHE)
Number of subjects: 500
Study 2564280 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered to 50% of the patients in each anaesthetic group
Number of subjects: 320
Study 2564280 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-neurolept technique
Number of subjects: 320
Study 2564280 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-halothane
Number of subjects: 320
Study 4936366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (1 Gm.)
Number of subjects: 24
Study 30317338 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized group (financial incentives based on physical activity)
Number of subjects: 56
Study 30317338 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-incentivized)
Number of subjects: 56
Study 28025686 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐NDL®
Number of subjects: 187
Study 28025686 — intervention group
Group type: COMPARATOR
Intervention: Monarc®
Number of subjects: 187
Study 25940636 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 80
Study 25940636 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 80
Study 23863876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg × 2)
Number of subjects: 18
Study 23863876 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m²)
Number of subjects: 18
Study 22078191 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA) performed by nurses
Number of subjects: 897
Study 22078191 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA) performed by physicians
Number of subjects: 897
Study 17428526 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent prosodic structure (vocatives)
Number of subjects: 0
Study 17428526 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate prosodic pattern
Number of subjects: 0
Study 17428526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate but infrequent prosodic structure
Number of subjects: 0
Study 17428526 — intervention group
Group type: COMPARATOR
Intervention: Congruent syntax-to-prosody relations
Number of subjects: 0
Study 16423873 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 166
Study 16423873 — intervention group
Group type: COMPARATOR
Intervention: No emergency revascularization
Number of subjects: 166
Study 14506952 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus calcitriol (0.25 microg bd)
Number of subjects: 81
Study 14506952 — intervention group
Group type: COMPARATOR
Intervention: HRT (piperazine estrone sulfate 0.625 - 1.25 mg/d +/− medroxyprogesterone acetate 2.5 - 5 mg/d)
Number of subjects: 81
Study 10573071 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 293
Study 10573071 — intervention group
Group type: COMPARATOR
Intervention: SIM
Number of subjects: 293
Study 8682134 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (Seloken ZOC 200 mg o.d.)
Number of subjects: 809
Study 8682134 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (Isoptin Retard 240 b.i.d.)
Number of subjects: 809
Study 8682134 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809
Study 8682134 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 809
Study 8682134 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Verapamil
Number of subjects: 809
Study 2303568 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP)
Number of subjects: 68
Study 2303568 — intervention group
Group type: COMPARATOR
Intervention: Stimulus control
Number of subjects: 68
Study 2303568 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 6171678 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 20
Study 6171678 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 20
Study 31072190 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 147
Study 31072190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 147
Study 31072190 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol and Ibuprofen
Number of subjects: 147
Study 28387125 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) approach
Number of subjects: 538
Study 28387125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar artery (UA) approach
Number of subjects: 538
Study 25491499 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3
Number of subjects: 62
Study 25491499 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3
Number of subjects: 62
Study 25491499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24736679 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (OL)
Number of subjects: 50
Study 24736679 — intervention group
Group type: COMPARATOR
Intervention: Stearic acid (STA)
Number of subjects: 50
Study 24736679 — intervention group
Group type: COMPARATOR
Intervention: Control (CHO)
Number of subjects: 50
Study 22270734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL) - Group I
Number of subjects: 56
Study 22270734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections with 0.5% lidocaine, 4 mL, mixed with 1 mL of nonparticulate betamethasone - Group II
Number of subjects: 56
Study 22270734 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful group patients (combined from both groups)
Number of subjects: 56
Study 19798060 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational phosphodiesterase type 5 inhibitor
Number of subjects: 211
Study 17621727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (650 mg, three times per day for 4 days)
Number of subjects: 126
Study 17621727 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 (25 mg, three times per day for 4 days)
Number of subjects: 126
Study 15831910 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 microg/day)
Number of subjects: 31
Study 15831910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11888840 — intervention group
Group type: COMPARATOR
Intervention: Testosterone plus placebo
Number of subjects: 0
Study 11888840 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus letrozole
Number of subjects: 0
Study 10084103 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 120
Study 10084103 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120
Study 10084103 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 100 micrograms kg‐1
Number of subjects: 120
Study 10084103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 7661937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril (6.25 mg initial dose titrated up to 50 mg twice daily)
Number of subjects: 58050
Study 7661937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release mononitrate (30 mg initial dose titrated up to 60 mg once daily)
Number of subjects: 58050
Study 7661937 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate (8 mmol initial bolus followed by 72 mmol for 24 hours)
Number of subjects: 58050
Study 3047333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with cyclophosphamide, fluorouracil, prednisone (CFP)
Number of subjects: 261
Study 30741739 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Lumen Imaging Probe (FLIP) distensibility index (DI)
Number of subjects: 79
Study 30741739 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIP metrics with normal anatomy
Number of subjects: 79
Study 30741739 — intervention group
Group type: EXPERIMENTAL
Intervention: DI cutoff of <2.8 as abnormal
Number of subjects: 79
Study 30741739 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIP DI
Number of subjects: 79
Study 28089141 — intervention group
Group type: COMPARATOR
Intervention: rHA vaccine at 7.5ug (no adjuvant)
Number of subjects: 321
Study 28089141 — intervention group
Group type: EXPERIMENTAL
Intervention: rHA vaccine at 3.8ug with 2% SE
Number of subjects: 321
Study 28089141 — intervention group
Group type: EXPERIMENTAL
Intervention: rHA vaccine at 7.5ug with 2% SE
Number of subjects: 321
Study 28089141 — intervention group
Group type: EXPERIMENTAL
Intervention: rHA vaccine at 15ug with 2% SE
Number of subjects: 321
Study 24512647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense focused ultrasound (IFUS) using 1.5-mm transducer
Number of subjects: 22
Study 24512647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense focused ultrasound (IFUS) using 3.0-mm transducer
Number of subjects: 22
Study 24512647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense focused ultrasound (IFUS)
Number of subjects: 22
Study 24129720 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent Micro Hip™
Number of subjects: 150
Study 24129720 — intervention group
Group type: COMPARATOR
Intervention: Nanos™
Number of subjects: 150
Study 24129720 — intervention group
Group type: COMPARATOR
Intervention: SL-Plus™ MIA
Number of subjects: 150
Study 21402976 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of docosahexaenoic acid (DHA)
Number of subjects: 38022
Study 21402976 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of eicosapentaenoic acid (EPA)
Number of subjects: 38022
Study 21402976 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 1 or more servings of fish per week
Number of subjects: 38022
Study 18772097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone-Misoprostol
Number of subjects: 0
Study 18772097 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 0
Study 20435258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (BSX) first
Number of subjects: 452
Study 20435258 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BAP) first
Number of subjects: 452
Study 16221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 21
Study 16221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg three times a day
Number of subjects: 21
Study 16221219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 21
Study 16221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 21
Study 16221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active treatments (Celecoxib and Indomethacin)
Number of subjects: 21
Study 12148101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-profiling hemodialysis with dialysate sodium concentration of 140 mmol/L (TAC(140))
Number of subjects: 11
Study 12148101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-profiling hemodialysis with dialysate sodium concentration of 147 mmol/L (TAC(147))
Number of subjects: 11
Study 12148101 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis with dialysate sodium concentration of 138 mmol/L (TAC(138))
Number of subjects: 11
Study 9544633 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 118
Study 9544633 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 118
Study 7920500 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms/d
Number of subjects: 256
Study 7920500 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms/d
Number of subjects: 256
Study 7920500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 3076790 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose enprofylline (2 mg/kg bolus and 1 mg/kg/hour infusion)
Number of subjects: 14